Bronchogen

Mechanism

A three-amino-acid peptide developed by Russian gerontologist Khavinson specifically targeting the lungs and bronchial tissue. Part of the same bioregulator family as Epithalon and other short peptides. Used to support respiratory function and potentially reduce age-related decline in lung capacity. Limited Western clinical data.

Effects

## Respiratory System [Tier 3 — Limited Human Data, Russian Clinical Studies] Bronchogen (Ala-Asp-Glu-Leu, tetrapeptide) is a Khavinson-class bioregulator peptide targeting bronchial epithelium and mucosal tissues. In Russian clinical studies, Bronchogen reportedly normalizes bronchial epithelial cell function by modulating gene expression involved in mucin production, ciliary function, and local immune defense. It is described as restoring optimal mucociliary clearance and reducing excessive mucus production in chronic obstructive conditions. Effects are proposed to be epigenetic — modulating chromatin structure and transcription factor access rather than acting as a direct receptor agonist. ## Immune System — Mucosal Immunity [Tier 3 — Preclinical/Limited Human Data] Bronchogen is reported to normalize secretory IgA levels in bronchial secretions and restore the balance of T-helper and T-suppressor lymphocytes in bronchial-associated lymphoid tissue (BALT). In animal models and limited human studies, it reportedly improved local immune defense against respiratory infections in elderly subjects with chronic bronchitis. ## Connective Tissue — Airway Remodeling [Tier 3 — Preclinical Data] Preclinical data suggest Bronchogen may modulate fibroblast activity in bronchial walls, potentially reducing the airway remodeling (fibrosis, smooth muscle hypertrophy) that characterizes chronic obstructive pulmonary disease. This effect is attributed to normalization of matrix metalloproteinase (MMP) expression.

Practitioner Guide

## Clinical Context Bronchogen is part of the Khavinson bioregulator peptide family developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is not approved by the FDA, EMA, or any major Western regulatory agency. All clinical data originates from Russian studies, many of which are published in Russian-language journals with limited peer review by Western standards. ### Typical Protocols (From Russian Clinical Literature) - **Oral capsules:** 10 mg daily for 10-30 days. Often used in cycles — 10 days on, 2-3 months off, repeat. - **Combination with Chonluten:** Frequently combined with Chonluten (another respiratory bioregulator) — Bronchogen targeting bronchial epithelium while Chonluten targets lung parenchyma. - **Target populations in Russian studies:** Elderly patients (60-80+ years) with chronic bronchitis, COPD, and frequent respiratory infections. ### Practitioner Considerations - Evidence base is very limited by Western clinical trial standards. No RCTs with Western regulatory-grade endpoints. - The proposed mechanism (epigenetic gene regulation by small peptides) is scientifically plausible but not rigorously validated. - Oral bioavailability of a tetrapeptide is theoretically very low, though proponents argue that the small size allows some GI absorption. - No known drug interactions (due to peptide nature and proposed epigenetic mechanism). - No reported serious adverse effects in available literature, but the safety database is small. - Best considered as an adjunctive/supportive therapy in patients already on evidence-based COPD/bronchitis treatment, not as a replacement for standard care.

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No human safety data during pregnancy. Bioregulator peptide modulating bronchial gene expression poses unknown risk to fetal pulmonary development.
  Action: Do not use during pregnancy.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Safety not established.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Research peptide. Not for pediatric use.
  Action: Do not provide to individuals under 18.
• caution — General use
  Limited human safety data. Russian bioregulator peptide without large-scale clinical trials or international regulatory approval. Not commercially available for standard therapeutic use.
  Action: Use with awareness of limited evidence base. Medical supervision recommended.

Evidence

• Short peptides stimulate cell regeneration in bronchial mucosa

  Khavinson V, Linkova N, Polyakova V, Kheifets O, Tarnovskaya S, Kvetnoy I (2011) — Bulletin of Experimental Biology and Medicine

  Bronchogen (Ala-Glu-Asp tripeptide) stimulated proliferation and differentiation of bronchial epithelial cells in vitro. The peptide promoted expression of surfactant proteins and markers of bronchial epithelial regeneration. Part of the Khavinson peptide bioregulation program — claimed to regulate gene expression in respiratory tissue. Evidence is limited to in vitro work from a single research group; no published clinical trials.

  emerging

Research Summary

## Tier 1 — Strong Clinical Evidence - None. No Western regulatory-approved indications. No Phase III RCTs by international standards. ## Tier 2 — Moderate Evidence - Russian clinical studies (Khavinson et al.) report improvement in pulmonary function tests (FEV1, FVC) in elderly COPD patients after 10-30 day oral courses (n=30-60 per study, open-label or small controlled trials) - Reported normalization of secretory IgA and mucociliary clearance in chronic bronchitis patients ## Tier 3 — Preclinical/Theoretical - In vitro studies show Bronchogen tetrapeptide interacts with DNA sequences in promoter regions of genes involved in bronchial epithelial function - Cell culture data demonstrating modulation of mucin gene expression and ciliary beat frequency - Proposed epigenetic mechanism (chromatin remodeling) is consistent with broader bioregulator peptide theory but not independently validated - Animal models (aged rats) show improved bronchial histology after Bronchogen administration - All research originates from a single research group/institute — independent replication absent